Irvine, CA-based x-ray technology developer Lumitron Technologies has secured breakthrough device designation from the U.S. Food and Drug Administration (FDA) for its Hyperview system.
First introduced in 2018, the Hyperview system uses K-edge subtraction imaging to enable contrast-enhanced imaging for the diagnosis of breast cancer, Lumitron said. The system is based on the company’s proprietary distributed charge laser-Compton technology and provides imaging that is both 100 times higher resolution and significantly safer than standard x-rays, according to the company.
Lumitron made the announcement on February 4, World Cancer Day, the company noted.